A Phase 1/2 interventional study of perflutren lipid microsphere in Acute Ischemic Stroke, sponsored by ImaRx Therapeutics. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-07-27.
Sponsored by ImaRx Therapeutics · Phase 1/2, Interventional, and Treatment
The study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere [Definity®]) and continuous monitoring with 2 MHz transcranial Doppler ultrasound (TCD) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.
7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.
Browse Stroke studies →ImaRx Therapeutics is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Also known as: Definity
Incidence of symptomatic intracranial hemorrhage
Time frame: 72 hours
Complete recanalization of the occluded artery (TIBI 4-5)
Time frame: End of treatment
NIHSS score of 0-2
Time frame: 24 hours
Favorable outcome (modified Rankin Scale or NIHSS 0-1)
Time frame: 3 months
No study locations are listed for this record.
This study is terminated, as verified in Jul 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ImaRx Therapeutics